Previous studies have suggested that the efficacy of an MDM2i and BETi combination in chronic myeloid leukemia (CML) comes from dual targeting of the p53 and c-MYC pathways, by MDM2i and BETi respectively47. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.